View in EDS HTML Full Text PDF Full Text

Telomerase inhibition is an effective therapeutic strategy in TERT promoter-mutant glioblastoma models with low tumor volume.

Saved in:
Bibliographic Details
Title: Telomerase inhibition is an effective therapeutic strategy in TERT promoter-mutant glioblastoma models with low tumor volume.
Authors: Aquilanti E; Division of Neuro Oncology, Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts, USA.; Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts, USA.; Cancer Program, Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA., Kageler L; Cancer Program, Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA., Watson J; Cancer Program, Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA., Baird DM; Division of Cancer and Genetics, School of Medicine, Cardiff University, Cardiff, UK., Jones RE; Division of Cancer and Genetics, School of Medicine, Cardiff University, Cardiff, UK., Hodges M; Division of Cancer and Genetics, School of Medicine, Cardiff University, Cardiff, UK., Szegletes ZM; Genetic Perturbation Platform, Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA., Doench JG; Genetic Perturbation Platform, Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA., Strathdee CA; Cancer Program, Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA., Figueroa JRMF; Division of Neuro Oncology, Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts, USA., Ligon KL; Department of Pathology, Brigham and Women's Hospital, Boston Children's Hospital, Dana Farber Cancer Institute, Boston, Massachusetts, USA., Beck M; Cancer Program, Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA., Wen PY; Division of Neuro Oncology, Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts, USA., Meyerson M; Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts, USA.; Cancer Program, Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA.; Center for Cancer Genomics, Dana Farber Cancer Institute, Boston, Massachusetts, USA.; Department of Genetics and Medicine, Harvard Medical School, Boston, Massachusetts, USA.
Source: Neuro-oncology [Neuro Oncol] 2023 Jul 06; Vol. 25 (7), pp. 1275-1285.
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
Journal Info: Publisher: Oxford University Press Country of Publication: England NLM ID: 100887420 Publication Model: Print Cited Medium: Internet ISSN: 1523-5866 (Electronic) Linking ISSN: 15228517 NLM ISO Abbreviation: Neuro Oncol Subsets: MEDLINE
Database: MEDLINE Ultimate
Full text is not displayed to guests.
FullText Links:
  – Type: pdflink
Text:
  Availability: 1
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 36694348
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Telomerase inhibition is an effective therapeutic strategy in TERT promoter-mutant glioblastoma models with low tumor volume.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Aquilanti+E%22">Aquilanti E</searchLink>; Division of Neuro Oncology, Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts, USA.; Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts, USA.; Cancer Program, Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA.<br /><searchLink fieldCode="AU" term="%22Kageler+L%22">Kageler L</searchLink>; Cancer Program, Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA.<br /><searchLink fieldCode="AU" term="%22Watson+J%22">Watson J</searchLink>; Cancer Program, Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA.<br /><searchLink fieldCode="AU" term="%22Baird+DM%22">Baird DM</searchLink>; Division of Cancer and Genetics, School of Medicine, Cardiff University, Cardiff, UK.<br /><searchLink fieldCode="AU" term="%22Jones+RE%22">Jones RE</searchLink>; Division of Cancer and Genetics, School of Medicine, Cardiff University, Cardiff, UK.<br /><searchLink fieldCode="AU" term="%22Hodges+M%22">Hodges M</searchLink>; Division of Cancer and Genetics, School of Medicine, Cardiff University, Cardiff, UK.<br /><searchLink fieldCode="AU" term="%22Szegletes+ZM%22">Szegletes ZM</searchLink>; Genetic Perturbation Platform, Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA.<br /><searchLink fieldCode="AU" term="%22Doench+JG%22">Doench JG</searchLink>; Genetic Perturbation Platform, Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA.<br /><searchLink fieldCode="AU" term="%22Strathdee+CA%22">Strathdee CA</searchLink>; Cancer Program, Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA.<br /><searchLink fieldCode="AU" term="%22Figueroa+JRMF%22">Figueroa JRMF</searchLink>; Division of Neuro Oncology, Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts, USA.<br /><searchLink fieldCode="AU" term="%22Ligon+KL%22">Ligon KL</searchLink>; Department of Pathology, Brigham and Women's Hospital, Boston Children's Hospital, Dana Farber Cancer Institute, Boston, Massachusetts, USA.<br /><searchLink fieldCode="AU" term="%22Beck+M%22">Beck M</searchLink>; Cancer Program, Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA.<br /><searchLink fieldCode="AU" term="%22Wen+PY%22">Wen PY</searchLink>; Division of Neuro Oncology, Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts, USA.<br /><searchLink fieldCode="AU" term="%22Meyerson+M%22">Meyerson M</searchLink>; Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts, USA.; Cancer Program, Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA.; Center for Cancer Genomics, Dana Farber Cancer Institute, Boston, Massachusetts, USA.; Department of Genetics and Medicine, Harvard Medical School, Boston, Massachusetts, USA.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22100887420%22">Neuro-oncology</searchLink> [Neuro Oncol] 2023 Jul 06; Vol. 25 (7), pp. 1275-1285.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article; Research Support, Non-U.S. Gov't
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Oxford+University+Press%22">Oxford University Press </searchLink><i>Country of Publication: </i>England <i>NLM ID: </i>100887420 <i>Publication Model: </i>Print <i>Cited Medium: </i>Internet <i>ISSN: </i>1523-5866 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2215228517%22">15228517 </searchLink><i>NLM ISO Abbreviation: </i>Neuro Oncol <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=36694348
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1093/neuonc/noad024
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 1275
    Titles:
      – TitleFull: Telomerase inhibition is an effective therapeutic strategy in TERT promoter-mutant glioblastoma models with low tumor volume.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Aquilanti E
      – PersonEntity:
          Name:
            NameFull: Kageler L
      – PersonEntity:
          Name:
            NameFull: Watson J
      – PersonEntity:
          Name:
            NameFull: Baird DM
      – PersonEntity:
          Name:
            NameFull: Jones RE
      – PersonEntity:
          Name:
            NameFull: Hodges M
      – PersonEntity:
          Name:
            NameFull: Szegletes ZM
      – PersonEntity:
          Name:
            NameFull: Doench JG
      – PersonEntity:
          Name:
            NameFull: Strathdee CA
      – PersonEntity:
          Name:
            NameFull: Figueroa JRMF
      – PersonEntity:
          Name:
            NameFull: Ligon KL
      – PersonEntity:
          Name:
            NameFull: Beck M
      – PersonEntity:
          Name:
            NameFull: Wen PY
      – PersonEntity:
          Name:
            NameFull: Meyerson M
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 06
              M: 07
              Text: 2023 Jul 06
              Type: published
              Y: 2023
          Identifiers:
            – Type: issn-electronic
              Value: 1523-5866
          Numbering:
            – Type: volume
              Value: 25
            – Type: issue
              Value: 7
          Titles:
            – TitleFull: Neuro-oncology
              Type: main
ResultId 1